Impact News +++ Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery (WSJ EN) +++ WARNER BROS DISCOVERY Aktie +13,44%

ABBISKO Aktie

>ABBISKO Performance

1 Woche: +3,9%

1 Monat: +47,2%

3 Monate: +83,3%

6 Monate: +106,6%

1 Jahr: +473,6%

laufendes Jahr: +256,2%

>ABBISKO Aktie

Name:

ABBISKO CAYMAN DL-,00001

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG0028A1085 / A3C4Y0

Symbol/ Ticker:

8ZD (Frankfurt)

Kürzel:

FRA:8ZD, ETR:8ZD, 8ZD:GR

Index:

Webseite:

https://www.abbisko.com/

Profil:

Abisko Cayman Ltd. is a company engaged in the pro..
>Volltext..

Marktkapitalisierung:

1335.6 Mio. EUR

Unternehmenswert:

1070.35 Mio. EUR

Umsatz:

72.45 Mio. EUR

EBITDA:

Nettogewinn:

17.35 Mio. EUR

Gewinn je Aktie:

0.03 EUR

Schulden:

15.2 Mio. EUR

Liquide Mittel:

89.38 Mio. EUR

Operativer Cashflow:

Bargeldquote:

11.28

Umsatzwachstum:

23.37%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ABBISKO, ABBISKO-B

Letzte Datenerhebung:

11.09.25

>ABBISKO Kennzahlen

Aktien/ Unternehmen:

Aktien: 680.11 Mio. St.

Frei handelbar: 69.01%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 226

Umsatz/Mitarb.: 0.27 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: -1.99%

Bewertung:

KGV: 63.96

KGV lG: 127.38

KUV: 17.18

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 100%

Gewinnmarge: 23.95%

Operative Marge: 13.34%

Managementeffizenz:

Gesamtkaprendite: 6.24%

Eigenkaprendite: 6.73%

>ABBISKO Peer Group

Es sind 101 Aktien bekannt.

>ABBISKO Chart & Kurs - Stuttgart

>ABBISKO News

16.06.25 - 04:39	Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC (PR Newswire)
	SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular......

10.06.25 - 06:06	Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT (PR Newswire)
	SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1......

26.05.25 - 06:16	Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC (PR Newswire)
	SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of......

13.05.25 - 05:36	Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress (PR Newswire)
	SHANGHAI, May 12, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the......

28.04.25 - 04:03	2025 AACR \| Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (PR Newswire)
	SHANGHAI, April 27, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results......

01.04.25 - 05:24	Abbisko Says Merck Exercised Option For Global Rights Of Pimicotinib (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 ......

01.04.25 - 02:51	Merck Exercised the Option for the Global Rights of Abbisko Therapeutics′s Pimicotinib (PR Newswire)
	SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million, under the......

28.03.25 - 06:33	Merck übt Option für weltweite Vermarktungsrechte für Pimicotinib aus (Dow Jones)
	DOW JONES--Der Pharma- und Technologiekonzern Merck hat eine Option zur Vermarktung des Wirkstoffkandidaten Pimicotinib von Abbisko Therapeutics in den USA und im Rest der Welt ausgeübt. ......

12.11.24 - 10:13	Merck KGaA: Phase III Trial Of Pimicotinib In Tenosynovial Giant Cell Tumor Meets Primary Endpoint (AFX)
	BERLIN (dpa-AFX) - Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by Abbisko ......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Es gibt Leute, die sind so langweilig, daß man mit ihnen in fünf Minuten einen ganzen Tag verliert. - Jules Renard

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram